Intertrust Announces ExpressPlay CA – Robust, Cost-Effective Conditional Access for Modern Broadcast Systems
As part of a major platform expansion of its ExpressPlay media monetization platform, Intertrust Technologies Corporation today announced ExpressPlay CA™, a new Conditional Access System (CAS) for smart devices. Built on the open standards-based Marlin DRM engine, ExpressPlay CA provides a modern, highly efficient and cost-effective CA system for TV network operators and broadcasters.
Unlike traditional CA systems that are cumbersome and expensive, ExpressPlay CA uses the same content protection engine as the ExpressPlay Marlin DRM profile. This allows an operator to service both broadband and broadcast devices with the same content protection software. The technology works whether or not a device is connected to the Internet, and delivers content and entitlement rights over the broadcast channel.
“For years, broadcasters and network TV operators were gatekept by conditional access providers who dictated onerous pricing and business terms in exchange for restrictive content protection, while Internet TV operators used cheap, efficient DRM sourced from multiple parties,” said Talal G. Shamoon, Intertrust’s chief executive officer. “ExpressPlay CA unites the best of both worlds – efficient, cost-effective CAS that performs better than traditional conditional access systems for a fraction of the price. ExpressPlay uses broadband-style technology for broadcast, bringing CAS into the 21st century.”
ExpressPlay CA supports premium content distribution models such as pay-per-view, on-demand, and time-boxed channels. When working in unison with ExpressPlay DRM, it can support sophisticated multi-device content sharing and device-to-device streaming.
“Broadcasters and Pay TV operators in Europe have waited for years for a single solution that meets all of their content protection needs,” said Alberto Sigismondi, chief executive officer of Italy’s Tivù, the parent company of TivùSat and TivùOn!. “We expect technologies like ExpressPlay CA to improve margins and revolutionize the way we protect and manage our valuable content.”
ExpressPlay CA does not require dedicated client hardware to operate and broadcasters can use their current head-end infrastructure. ExpressPlay CA supports DVB Simulcrypt and can be deployed alongside other conditional access systems if needed. The technology is also fully compatible with HbbTV, and provides a complete open standards solution for adopters.
With both broadcasters and over-the-top TV providers eager to offer UHD content, ExpressPlay CA and ExpressPlay DRM together provide a consistent solution to meet a content owner’s requirements for protecting UHD content.
About Intertrust Technologies Corporation
Intertrust provides trusted computing products and services to leading global corporations – from mobile and CE manufacturers and service providers to enterprise software platform companies. These products include the world’s leading digital rights management, software tamper resistance and privacy-driven data platforms for AdTech, DNA storage, and IoT.
Founded in 1990, Intertrust is based in Silicon Valley, with regional offices in London, Tokyo, Seoul and Beijing. The Company has a legacy of invention, and its fundamental contributions in the areas of computer security and digital trust are globally recognized. Intertrust holds hundreds of patents that are key to Internet security, trust, and privacy management components of operating systems, trusted mobile code and networked operating environments, web services, and cloud computing. Additional information is available at intertrust.com, or follow us on Twitter or LinkedIn.
Actual Agency for Intertrust
Brian Regan, 908-399-7161
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
LivaNova Enters into Binding Letter of Intent to Sell its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation for $190 Million20.11.2017 08:43 | Pressemelding
LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) and MicroPort Scientific Corporation (HK:00853) (“MicroPort”) today announced that the companies have entered into a binding Letter of Intent (“LOI”) for the sale of LivaNova’s Cardiac Rhythm Management (“CRM”) Business Franchise to MicroPort for $190 million in cash. The CRM Business Franchise develops, manufactures and markets products for the diagnosis, treatment and management of heart rhythm disorders and heart failures. CRM products include high-voltage defibrillators, cardiac resynchronization therapy devices and low-voltage pacemakers. The CRM Business Franchise generated approximately $249 million in net sales in fiscal year 2016 and has approximately 900 employees with operations chiefly in Clamart, France; Saluggia, Italy; and Santo Domingo, Dominican Republic. MicroPort is a leading medical device company, focused on innova
Chugai's Bispecific Antibody Emicizumab Meets Primary Endpoint in Phase lll Study20.11.2017 08:29 | Pressemelding
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the primary endpoint has been met for the global phase lll HAVEN 3 (NCT02847637) study evaluating emicizumab (ACE910) subcutaneous injection, once a week and once every two weeks, in patients with hemophilia A (12 years of age or older) without inhibitors to factor Vlll. A statistically significant reduction in the number of bleeds was confirmed in patients treated with emicizumab prophylaxis compared to those receiving no prophylactic treatment. The study also met a secondary endpoint that once-weekly emicizumab prophylaxis was superior to factor VIII prophylaxis, as demonstrated by a statistically significant and clinically meaningful reduction in treated bleeds in an intra-patient comparison of patients receiving emicizumab prophylaxis compared to their prior factor VIII prophylaxis. The most common adverse events with em
Fiorano Launches PSD2 Solution for Banks for Seamless Regulatory Compliance20.11.2017 08:00 | Pressemelding
Fiorano Software, a proven global leader in Integration Middleware and API Management, today announced the launch of Fiorano PSD2, a platform solution enabling banks to comply with the European Union’s Revised Payment Service Directive (PSD2) regulations. Fiorano’s end-to-end PSD2 solution is built on the industry's leading banking Integration and API Management infrastructure serving as an onramp for future eDigital Banking initiatives. Banks across Europe need to be PSD2 compliant by January 2018. They are also facing severe competition from FinTechs to improve online payments, customer engagement experiences and making cross-border payments safer. “By building on PSD2 as a solution on top of a tightly integrated API Management and ESB platform, Fiorano masks complex technical details, dramatically simplifies the time and effort for compliance,” said Mr. Atul Saini, CEO of Fio
Synteract Thought Leaders to Speak & Exhibit at Partnerships in Clinical Trials Europe in Amsterdam20.11.2017 08:00 | Pressemelding
(Booth #17) – Thought leaders from Synteract, a full-service, international contract research organization (CRO), will exhibit and present at Partnerships in Clinical Trials Europe (PCT), November 28-29, Amsterdam, Netherlands. With awareness of the shifting CRO landscape and the complexity this represents to biopharma companies as they make critical outsourcing decisions, Synteract invites attendees to “Pause to rethink what matters most from your CRO.” Vice President, Global Medical and Regulatory Affairs at Synteract, Dr. Martine Dehlinger-Kremer, will speak on “The EU Clinical Trials Regulation: Are you prepared for its implementation?” at the event on Tuesday, November 28 at noon. She will address how evolving industry needs are driving momentum towards implementation of a new regulation governing clinical trials, the expected impact on sponsors and necessary steps toward p
Record Attendance at Japan Content Showcase 2017!20.11.2017 03:00 | Pressemelding
Japan Content Showcase 2017 was held October 23-26 at Ikebukuro Sunshine City and the Shibuya Excel Hotel Tokyu. A record 19,549 people participated in sales meetings, excluding the TIMM Showcase Live. Other new records this year were 371 exhibiting groups from 27 countries and regions and 1,549 buyers from 48 countries and regions. There was a significant increase in overseas buyers this year, the 1022 foreign registrations representing an increase of more than 10% over last year. The number of non-Japanese Asian buyers increased by 6%, North Americans by 13%, South Americans by 44%, and Europeans by 49%. The number of Middle Eastern buyers doubled, and there were more than five times the number of Russian buyers as last year. French buyers were up 70%, Italians 60%, British 75%, and Germans 50%. Business matching was a new service offered by the organizers this year. Meeti
Shell, bio-bean and Coffee-Drinkers Collaborate to Help Power London’s Buses20.11.2017 00:01 | Pressemelding
Shell and bio-bean announce that together they are helping to power some of London’s buses using a biofuel made partly from waste coffee grounds. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005060/en/ Shell and bio-bean announce that together they are helping to power some of London's buses using a biofuel made partly from waste coffee grounds (Photo: Business Wire) The B20 biofuel contains a 20% bio-component which contains part coffee oil. The biofuel is being added to the London bus fuel supply chain and will help to power some of the buses; without need for modification. Biofuel provides a cleaner, more sustainable energy solution for buses across London’s network by decreasing emissions1. “Our Coffee Logs have already become the fuel of choice for households looking for a
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom